Wangsaputra, Vincent Kharisma
Unknown Affiliation

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Tata Laksana Terkini Dermatitis Atopik Sedang dan Berat: Dari Patogenesis hingga Terobosan Tata Laksana. Putra, Muhammad Alifian Remifta; Wangsaputra, Vincent Kharisma; Penantian, Raya Makarim
Cermin Dunia Kedokteran Vol 51 No 7 (2024): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i7.1096

Abstract

Atopic dermatitis (AD), characterized by recurrent eczematous lesions and pruritus, is a major contributor to the total global burden of disability. The common management practice includes patient education and topical emollients and is heavily reliant on the use of anti-inflammatory agents with systemic corticosteroids. Monoclonal antibodies provide a novel, targeted approach towards specific cytokines. This study aims to highlight the novel systemic therapeutic drug aimed at specific targets. A comprehensive literature review utilizes databases including EMBASE, EBSCOhost, PubMed, Scopus, and Wiley Online Library, using keywords: “monoclonal antibody” AND “therapy” AND “atopic dermatitis”. Relevant papers containing different updates in atopic dermatitis management and the utilization of monoclonal antibodies are included in this review. The current regimen of monoclonal antibodies offers better management of moderate-to-severe AD. Monoclonal antibodies have become a promising therapy as they demonstrate better therapeutic effects in terms of skin barrier protection and anti-inflammatory and pruritusreducing effects. However, its application still faces various challenges such as side effects and infections. The heterogeneity and relapsing nature also add to the complexity and risk profile of AD management.